体外连接视黄酸受体α纠正克罗恩病患者缺陷性调节性T细胞
该研究比较克罗恩病患者与健康对照的调节性T细胞(Treg)整合素α4β7表达,并将患者Treg体外扩增后以雷帕霉素联合视黄酸受体α(RARA)激动剂RAR568处理。结果显示患者Treg的α4β7表达低于对照,RAR568处理可诱导α4β7、CD62L和FOXP3高表达并增强抑制与迁移活性,作者认为这些细胞可能用于治疗克罗恩病。
要点
- 克罗恩病患者Treg细胞整合素α4β7表达水平低于健康对照。
- 雷帕霉素联合RAR568处理患者Treg可高表达α4β7、CD62L和FOXP3。
- RAR568处理后的Treg在剪切流下迁移并优先归巢至人肠异种移植小鼠肠道。
核心结论
- 克罗恩病患者Treg细胞整合素α4β7表达低于健康对照。
- 患者体外扩增Treg经雷帕霉素联合RARA激动剂处理后诱导α4β7表达,在培养及小鼠肠异种移植中具有抑制和迁移活性。
- 作者认为这些细胞可能被开发用于治疗克罗恩病。
研究设计与样本
- 研究比较克罗恩病患者与健康对照外周血及固有层分离Treg的整合素α4β7水平,并进行体外扩增、基因表达谱分析、细胞因子挑战、抑制实验、流式腔室实验及人肠异种移植SCID小鼠研究。
- 临床试验注册号NCT03185000。
主要发现
- 克罗恩病患者Treg细胞整合素α4β7表达低于对照。
- 患者Treg与雷帕霉素及RARA激动剂RAR568共孵育后,整合素α4β7、CD62L和FOXP3表达高于雷帕霉素单用或雷帕霉素联合全反式维甲酸处理。
- 上述Treg在实验中抑制活性增加、在剪切流条件下迁移、不产生炎性细胞因子,且RAR568对细胞稳定性或谱系定向无影响。
- 荧光标记的RAR568处理Treg归巢至肠异种移植物的可能性显著高于对照培养基扩增的Treg。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Crohn's disease (CD) is characterized by an imbalance of effector and regulatory T cells in the intestinal mucosa. The efficacy of anti-adhesion therapies led us to investigate whether impaired trafficking of T-regulatory (Treg) cells contributes to the pathogenesis of CD. We also investigated whether proper function could be restored to Treg cells by ex vivo expansion in the presence of factors that activate their regulatory activities. METHODS: We measured levels of the integrin α4β7 on Treg cells isolated from peripheral blood or lamina propria of patients with CD and healthy individuals (controls). Treg cells were expanded ex vivo and incubated with rapamycin with or without agonists of the retinoic acid receptor-α (RARA), and their gene expression profiles were analyzed. We also studied the cells in cytokine challenge, suppression, and flow chamber assays and in SCID mice with human intestinal xenografts. RESULTS: We found that Treg cells from patients with CD express lower levels of the integrin α4β7 than Treg cells from control patients. The pathway that regulates the expression of integrin subunit α is induced by retinoic acid (RA). Treg cells from patients with CD incubated with rapamycin and an agonist of RARA (RAR568) expressed high levels of integrin α4β7, as well as CD62L and FOXP3, compared with cells incubated with rapamycin or rapamycin and all-trans retinoic acid. These Treg cells had increased suppressive activities in assays and migrated under conditions of shear flow; they did not produce inflammatory cytokines, and RAR568 had no effect on cell stability or lineage commitment. Fluorescently labeled Treg cells incubated with RAR568 were significantly more likely to traffic to intestinal xenografts than Treg cells expanded in control medium. CONCLUSIONS: Treg cells from patients with CD express lower levels of the integrin α4β7 than Treg cells from control patients. Incubation of patients' ex vivo expanded Treg cells with rapamycin and an RARA agonist induced expression of α4β7 and had suppressive and migratory activities in culture and in intestinal xenografts in mice. These cells might be developed for treatment of CD. ClinicalTrials.gov, Number: NCT03185000.
引用
- Goldberg R, Scotta C, Cooper D, et al. Correction of Defective T-Regulatory Cells From Patients With Crohn's Disease by Ex Vivo Ligation of Retinoic Acid Receptor-α. Gastroenterology. 2019. PMID: 30710527. doi:10.1053/j.gastro.2019.01.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。